Kairos Pharma, Ltd.

Healthcare · Biotechnology · United States

Last price 0.53 USD (Oct 30, 2026, 4:00 PM) · Market cap 1.79M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company’s pro...